{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T06:12:18Z","timestamp":1793686338316,"version":"4.5.1"},"reference-count":95,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T00:00:00Z","timestamp":1649203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Psoriatic arthritis (PsA) is a chronic autoimmune inflammatory joint disease related to psoriasis (PsO). The risk of PsA patients with cardiovascular disease (CVD) is significantly higher than that of the general population. At present, the relevant mechanism is not clear, chronic inflammation and traditional cardiovascular risk factors are the most important factors for the increased risk of CVD in PsA patients. Early assessment of the risk of PsA patients with CVD, and active control of the disease activity of PsA patients and intervention of traditional cardiovascular risk factors can delay the progression of CVD risk. This article reviews the epidemiology and pathogenesis between PsA and CVD, and reviews the latest developments in the risk assessment and management of CVD in PsA patients.<\/jats:p>","DOI":"10.3389\/fcvm.2022.835439","type":"journal-article","created":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T06:48:03Z","timestamp":1649227683000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Related Risk Factors and Treatment Management of Psoriatic Arthritis Complicated With Cardiovascular Disease"],"prefix":"10.3389","volume":"9","author":[{"given":"Zhoulan","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianyu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuexue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengqiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gailian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,6]]},"reference":[{"key":"B1","volume-title":"World Health Statistics Overview 2019: Monitoring Health for the SDGs, Sustainable Development Goals","year":"2019"},{"key":"B2","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1080\/09546634.2019.1605142","article-title":"Psoriatic arthritis for dermatologists","volume":"31","author":"Gottlieb","year":"2020","journal-title":"J Dermatolog Treat."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1759720X211027712","DOI":"10.1177\/1759720X211027712","article-title":"Association of C-reactive protein and non-steroidal anti-inflammatory drugs with cardiovascular events in patients with psoriatic arthritis: a time-dependent Cox regression analysis","volume":"13","author":"Lam","year":"2021","journal-title":"Ther Adv Musculoskelet Dis."},{"key":"B4","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1159\/000345623","article-title":"Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study","volume":"225","author":"Esposito","year":"2012","journal-title":"Dermatology."},{"key":"B5","doi-asserted-by":"publisher","first-page":"adv00566","DOI":"10.2340\/00015555-3879","article-title":"Epidemiology, comorbidity and risk factors for psoriatic arthritis: a health insurance claims database analysis","volume":"101","author":"Maximilian","year":"2021","journal-title":"Acta Derm Venereol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"101689","DOI":"10.1016\/j.berh.2021.101689","article-title":"Cardiovascular disease and depression in psoriatic arthritis: multidimensional comorbidities requiring multidisciplinary management","volume":"35","author":"So","year":"2021","journal-title":"Best Pract Res Clin Rheumatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1759720X21998279","DOI":"10.1177\/1759720X21998279","article-title":"Psoriatic arthritis and the association with cardiometabolic disease: a narrative review","volume":"13","author":"Karmacharya","year":"2021","journal-title":"Ther Adv Musculoskelet Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/jdv.12163","article-title":"Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review","volume":"27","author":"Horreau","year":"2013","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1136\/annrheumdis-2011-201194","article-title":"Cardiovascular comorbidities in patients with psoriatic arthritis: a systematic review","volume":"72","author":"Jamnitski","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"B11","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1136\/annrheumdis-2014-205675","article-title":"Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study","volume":"74","author":"Ogdie","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1007\/s10067-019-04528-y","article-title":"Cardiac and cardiovascular morbidities in patients with psoriatic arthritis: a population-based case control study","volume":"38","author":"Kibari","year":"2019","journal-title":"Clin Rheumatol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1080\/03009742.2019.1672783","article-title":"Cardiovascular risk factors are highly overrepresented in Swedish patients with psoriatic arthritis compared with the general population","volume":"49","author":"Landgren","year":"2020","journal-title":"Scand J Rheumatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/acr.22926","article-title":"Risk of cardiovascular morbidity in patients with psoriatic arthritis: a meta-analysis of observational studies","volume":"69","author":"Polachek","year":"2017","journal-title":"Arthritis Care Res."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1136\/annrheumdis-2016-210275","article-title":"Incident myocardial infarction associated with major types of arthritis in the general population: a systematic review and meta-analysis","volume":"76","author":"Schieir","year":"2017","journal-title":"Ann Rheum Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1093\/rheumatology\/key286","article-title":"Risk of type 2 diabetes and cardiovascular disease in an incident cohort of people with psoriatic arthritis: a population-based cohort study","volume":"58","author":"Charlton","year":"2019","journal-title":"Rheumatology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1136\/annrheumdis-2012-201497","article-title":"The burden of carotid artery plaques is higher in patients with psoriatic arthritis compared with those with psoriasis alone","volume":"72","author":"Eder","year":"2013","journal-title":"Ann Rheum Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1007\/s12325-021-01698-7","article-title":"Clinical burden of concomitant joint disease in psoriasis: a US-linked claims and electronic health records database analysis","volume":"38","author":"Skornicki","year":"2021","journal-title":"Adv Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1759720X20976975","DOI":"10.1177\/1759720X20976975","article-title":"Higher depression rates and similar cardiovascular comorbidity in psoriatic arthritis compared with rheumatoid arthritis and diabetes mellitus","volume":"12","author":"Fragoulis","year":"2020","journal-title":"Ther Adv Musculoskelet Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1002\/acr.23567","article-title":"Incidence and prevalence of major adverse cardiovascular events in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis","volume":"70","author":"Lauper","year":"2018","journal-title":"Arthritis Care Res."},{"key":"B21","article-title":"Cardiovascular risk stratification in axial spondyloarthritis: carotid ultrasound is more sensitive than coronary artery calcification score to detect high-cardiovascular risk axial spondyloarthritis patients","author":"Rueda-Gotor","year":"2018","journal-title":"Clin Exp Rheumatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.3899\/jrheum.160070","article-title":"Disease activity and increased risk of cardiovascular death among patients with psoriatic arthritis","volume":"43","author":"Juneblad","year":"2016","journal-title":"J Rheumatol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00296-016-3487-2","article-title":"Updates on cardiovascular comorbidities associated with psoriatic diseases: epidemiology and mechanisms","volume":"37","author":"Yim","year":"2017","journal-title":"Rheumatol Int."},{"key":"B24","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.autrev.2011.05.022","article-title":"Atherosclerosis in psoriatic arthritis","volume":"10","author":"Ramonda","year":"2011","journal-title":"Autoimmun Rev."},{"key":"B25","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.semarthrit.2016.05.011","article-title":"Active peripheral inflammation is associated with pro-atherogenic lipid profile in psoriatic arthritis","volume":"46","author":"Shrestha","year":"2016","journal-title":"Semin Arthritis Rheum."},{"key":"B26","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1055\/s-0036-1584918","article-title":"Atherosclerosis in psoriatic arthritis: a multiparametric analysis using imaging technique and laboratory markers of inflammation and vascular function","volume":"25","author":"Garg","year":"2016","journal-title":"Int J Angiol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/j.1600-0625.2011.01261.x","article-title":"The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity","volume":"20","author":"Boehncke","year":"2011","journal-title":"Exp Dermatol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13075-015-0570-0","article-title":"Cumulative inflammatory burden is independently associated with increased arterial stiffness in patients with psoriatic arthritis: a prospective study","volume":"17","author":"Shen","year":"2015","journal-title":"Arthritis Res Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1002\/art.40389","article-title":"Higher coronary plaque burden in psoriatic arthritis is independent of metabolic syndrome and associated with underlying disease severity","volume":"70","author":"Szentpetery","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1177\/1203475415602842","article-title":"Psoriasis as an independent risk factor for cardiovascular disease: an epidemiologic analysis using a national database","volume":"20","author":"Lai","year":"2016","journal-title":"J Cutan Med Surg."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1136\/annrheumdis-2014-205267","article-title":"Increased burden of inflammation over time is associated with the extent of atherosclerotic plaques in patients with psoriatic arthritis","volume":"74","author":"Eder","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3109\/07853890.2015.1031822","article-title":"Cardiovascular risk markers in patients with psoriatic arthritis: a meta-analysis of literature studies","volume":"47","author":"Di Minno","year":"2015","journal-title":"Ann Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1007\/s10067-020-05088-2","article-title":"Enthesitis and joint erosions are disease traits associated with cardiovascular risk in psoriatic arthritis","volume":"39","author":"Lorenzo","year":"2020","journal-title":"Clin Rheumatol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1136\/annrheumdis-2021-220782","article-title":"Nail involvement in psoriatic arthritis patients is an independent risk factor for carotid plaque","volume":"80","author":"Colunga-Pedraza","year":"2021","journal-title":"Ann Rheum Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1136\/annrheumdis-2015-207980","article-title":"Incidence and predictors for cardiovascular events in patients with psoriatic arthritis","volume":"75","author":"Eder","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.semarthrit.2018.02.002","article-title":"Dactylitis: a hallmark of psoriatic arthritis","volume":"48","author":"Kaeley","year":"2018","journal-title":"Semin Arthritis Rheum."},{"key":"B37","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/ijms19010058","article-title":"Cardiometabolic comorbidities in psoriasis and psoriatic arthritis","author":"Puig","year":"2017","journal-title":"Int J Mol Sci."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1002\/acr.23171","article-title":"Incidence and prevalence of cardiovascular risk factors among patients with rheumatoid arthritis, psoriasis, or psoriatic arthritis","volume":"69","author":"Radner","year":"2017","journal-title":"Arthritis Care Res."},{"key":"B39","doi-asserted-by":"publisher","first-page":"378","DOI":"10.3899\/jrheum.170379","article-title":"Gaps in diagnosis and treatment of cardiovascular risk factors in patients with psoriatic disease: an international multicenter study","volume":"45","author":"Eder","year":"2018","journal-title":"J Rheumatol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"56","DOI":"10.3390\/medicina56080415","article-title":"The number of traditional cardiovascular risk factors is independently correlated with disease activity in patients with psoriatic arthritis","author":"Ferraz-Amaro","year":"2020","journal-title":"Medicina."},{"key":"B41","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/jcm6070068","article-title":"Pathogenic role of IL-17-producing immune cells in obesity, and related inflammatory diseases","author":"Chehimi","year":"2017","journal-title":"J Clin Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.3899\/jrheum.161402","article-title":"Psoriatic disease 10 years later","volume":"44","author":"Scarpa","year":"2017","journal-title":"J Rheumatol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1111\/1346-8138.13968","article-title":"Hyperuricemia is an independent risk factor for psoriatic arthritis in psoriatic patients","volume":"44","author":"Tsuruta","year":"2017","journal-title":"J Dermatol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.semarthrit.2008.06.001","article-title":"Asymptomatic hyperuricemia and serum uric acid concentration correlate with subclinical atherosclerosis in psoriatic arthritis patients without clinically evident cardiovascular disease","volume":"39","author":"Gonzalez-Gay","year":"2009","journal-title":"Semin Arthritis Rheum."},{"key":"B45","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3899\/jrheum.170384","article-title":"Characteristic and outcome of psoriatic arthritis patients with hyperuricemia","volume":"45","author":"AlJohani","year":"2018","journal-title":"J Rheumatol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ijcard.2016.08.129","article-title":"Exploring cardiovascular disease risk evaluation in patients with inflammatory joint diseases","volume":"223","author":"Semb","year":"2016","journal-title":"Int J Cardiol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.atherosclerosis.2015.12.011","article-title":"Vitamin D receptor GATG haplotype association with atherosclerotic disease in patients with rheumatoid arthritis","volume":"245","author":"Lopez-Mejias","year":"2016","journal-title":"Atherosclerosis."},{"key":"B48","doi-asserted-by":"publisher","first-page":"R146","DOI":"10.1186\/ar4608","article-title":"Interferon regulatory factor 5 genetic variants are associated with cardiovascular disease in patients with rheumatoid arthritis","volume":"16","author":"Garcia-Bermudez","year":"2014","journal-title":"Arthritis Res Ther."},{"key":"B49","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1097\/RHU.0000000000000306","article-title":"Rates of cardiovascular disease and major adverse cardiovascular events in patients with psoriatic arthritis compared to patients without psoriatic arthritis","volume":"21","author":"Li","year":"2015","journal-title":"J Clin Rheumatol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/pds.3890","article-title":"Risks of hypertension associated with cyclosporine, nonsteroidal anti-inflammatory drugs, and systemic glucocorticoids in patients with psoriasis: a nationwide population-based nested case-control study in Taiwan","volume":"25","author":"Lee","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B51","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","article-title":"EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update","volume":"76","author":"Agca","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"B52","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Ann Rheum Dis."},{"key":"B53","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1080\/03009742.2021.1920169","article-title":"Degree of arterial stiffness is comparable across inflammatory joint disease entities","volume":"76","author":"Fohse","year":"2021","journal-title":"Scand J Rheumatol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1016\/j.amjcard.2011.06.054","article-title":"Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease","volume":"108","author":"Micha","year":"2011","journal-title":"Am J Cardiol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s13075-017-1439-1","article-title":"Methotrexate and anti-tumor necrosis factor treatment improves endothelial function in patients with inflammatory arthritis","volume":"19","author":"Deyab","year":"2017","journal-title":"Arthritis Res Ther."},{"key":"B56","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/acr.23875","article-title":"Comparative risk of cardiovascular events with biologic and synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"72","author":"Singh","year":"2020","journal-title":"Arthritis Care Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s13075-018-1669-x","article-title":"Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study","volume":"20","author":"Lee","year":"2018","journal-title":"Arthritis Res Ther."},{"key":"B58","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2174\/138161282004140213123852","article-title":"Endothelial dysfunction and the effects of TNF inhibitors on the endothelium in psoriasis and psoriatic arthritis: a systematic review","volume":"20","author":"Brezinski","year":"2014","journal-title":"Curr Pharm Des."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1517\/14740338.2015.1111870","article-title":"Cardiovascular effects of Etanercept in patients with psoriatic arthritis: evidence from the cardiovascular risk in rheumatic diseases database","volume":"14","author":"Di Minno","year":"2015","journal-title":"Expert Opin Drug Saf."},{"key":"B60","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.trsl.2015.05.006","article-title":"Targeting inflammation in the prevention of cardiovascular disease in patients with inflammatory arthritis","volume":"167","author":"Shen","year":"2016","journal-title":"Transl Res."},{"key":"B61","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s10067-017-3657-y","article-title":"The effect of TNF-a antagonists on aortic stiffness and wave reflections: a meta-analysis","volume":"37","author":"Vlachopoulos","year":"2018","journal-title":"Clin Rheumatol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1002\/art.40366","article-title":"Association of tumor necrosis factor inhibitor treatment with reduced indices of subclinical atherosclerosis in patients with psoriatic disease","volume":"70","author":"Eder","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"B63","doi-asserted-by":"crossref","first-page":"158","DOI":"10.55563\/clinexprheumatol\/3qiqk3","article-title":"Subclinical atherosclerosis evolution during 5 years of anti-TNF-alpha treatment in psoriatic arthritis patients","volume":"39","author":"Ortolan","year":"2021","journal-title":"Clin Exp Rheumatol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.reumae.2021.05.003","article-title":"Psoriatic arthritis: interaction between cardiometabolic diseases and inflammatory burden of the disease","volume":"51","author":"Lorenzo Martin","year":"2021","journal-title":"Reumatol Clin."},{"key":"B65","doi-asserted-by":"publisher","first-page":"e0220079","DOI":"10.1371\/journal.pone.0220079","article-title":"Tumor necrosis factor inhibitors are associated with reduced complement activation in spondylarthropathies: an observational study","volume":"14","author":"Hokstad","year":"2019","journal-title":"PLoS ONE"},{"key":"B66","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/s12016-016-8560-9","article-title":"The effect of TNF inhibitors on cardiovascular events in psoriasis and psoriatic arthritis: an updated meta-analysis","volume":"51","author":"Yang","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1001\/jamadermatol.2019.0001","article-title":"Association of ustekinumab vs TNF inhibitor therapy with risk of atrial fibrillation and cardiovascular events in patients with psoriasis or psoriatic arthritis","volume":"155","author":"Lee","year":"2019","journal-title":"JAMA Dermatol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1093\/rheumatology\/keab522","article-title":"Risk of major adverse cardiovascular events in patients initiating biologics\/apremilast for psoriatic arthritis: a nationwide cohort study","volume":"47","author":"Pina Vegas","year":"2021","journal-title":"Rheumatology."},{"key":"B69","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/1346-8138.15293","article-title":"Real life experience of apremilast in psoriasis and arthritis psoriatic patients: preliminary results on metabolic biomarkers","volume":"47","author":"Mazzilli","year":"2020","journal-title":"J Dermatol"},{"key":"B70","article-title":"SAT0331 Inflammatory markers and adipokines related to cardiovascular risk and metabolic comorbidities in psoriatic arthritis in vivo effects of apremilast","author":"De La Rosa","year":"2018","journal-title":"Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13\u201316 June 2018"},{"key":"B71","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.pharep.2018.03.009","article-title":"Apremilast prevent doxorubicin-induced apoptosis and inflammation in heart through inhibition of oxidative stress mediated activation of NF-kappaB signaling pathways","volume":"70","author":"Imam","year":"2018","journal-title":"Pharmacol Rep."},{"key":"B72","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1093\/rheumatology\/keaa683","article-title":"The risks of major cardiac events among patients with psoriatic arthritis treated with apremilast, biologics, DMARDs or corticosteroids","volume":"60","author":"Persson","year":"2021","journal-title":"Rheumatology."},{"key":"B73","unstructured":"Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease-results of the IMAPA study138795 FergusonLD CathcartS RimmerD SempleG BrooksbankK PatersonC 10.1093\/rheumatology\/keab47434097014Rheumatology.712021"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1002\/acr.23930","article-title":"Changes in lipid levels and incidence of cardiovascular events following tofacitinib treatment in patients with psoriatic arthritis: a pooled analysis across phase III and long-term extension studies","volume":"71","author":"Gladman","year":"2019","journal-title":"Arthritis Care Res"},{"key":"B75","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1177\/1759720X19895492","article-title":"Effect of tofacitinib on cardiovascular events and all-cause mortality in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis of randomized controlled trials","author":"Xie","year":"2019","journal-title":"Ther Adv Musculoskelet Dis."},{"key":"B76","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1080\/21691401.2019.1573740","article-title":"Tofacitinib inhibits ox-LDL-induced adhesion of THP-1 monocytes to endothelial cells","volume":"47","author":"Yang","year":"2019","journal-title":"Artif Cells Nanomed Biotechnol."},{"key":"B77","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s40264-020-00904-9","article-title":"An integrated analysis of the safety of tofacitinib in psoriatic arthritis across phase III and long-term extension studies with comparison to real-world observational data","volume":"43","author":"Burmester","year":"2020","journal-title":"Drug Saf."},{"key":"B78","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3390\/ijms17081255","article-title":"Serum interleukin-18, fetuin-A, soluble intercellular adhesion molecule-1, and endothelin-1 in ankylosing spondylitis, psoriatic arthritis, and SAPHO syndrome","author":"Przepiera-Bedzak","year":"2016","journal-title":"Int J Mol Sci."},{"key":"B79","first-page":"774","article-title":"Hyperlipoproteinaemia(a) in patients with spondyloarthritis: results of the cardiovascular in rheumatology (CARMA) project","volume":"37","author":"Garcia-Gomez","year":"2019","journal-title":"Clin Exp Rheumatol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1186\/s13075-016-1074-2","article-title":"The impact of identifying carotid plaque on addressing cardiovascular risk in psoriatic arthritis","volume":"18","author":"Lucke","year":"2016","journal-title":"Arthritis Res Ther."},{"key":"B81","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.3899\/jrheum.160053","article-title":"Predictive value of arterial stiffness and subclinical carotid atherosclerosis for cardiovascular disease in patients with rheumatoid arthritis","volume":"43","author":"Ikdahl","year":"2016","journal-title":"J Rheumatol."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.3899\/jrheum.190729","article-title":"Disease activity influences cardiovascular risk reclassification based on carotid ultrasound in patients with psoriatic arthritis","volume":"47","author":"Palmou-Fontana","year":"2020","journal-title":"J Rheumatol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"682","DOI":"10.3899\/jrheum.181223","article-title":"Role of carotid ultrasound and systematic coronary risk evaluation charts for the cardiovascular risk stratification of patients with psoriatic arthritis","volume":"47","author":"Martinez-Vidal","year":"2020","journal-title":"J Rheumatol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s00296-016-3617-x","article-title":"High prevalence of subclinical atherosclerosis in psoriatic arthritis patients: a study based on carotid ultrasound","volume":"37","author":"Ibanez-Bosch","year":"2017","journal-title":"Rheumatol Int."},{"key":"B85","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/joim.13311","article-title":"Prevalence and severity of coronary artery disease linked to prognosis in psoriasis and psoriatic arthritis patients: a multi-centre cohort study","volume":"290","author":"Tinggaard","year":"2021","journal-title":"J Intern Med."},{"key":"B86","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jbspin.2017.07.002","article-title":"Is the SCORE chart underestimating the real cardiovascular (CV) risk of patients with psoriatic arthritis? Prevalence of subclinical CV disease detected by carotid ultrasound","volume":"85","author":"Martinez-Vidal","year":"2018","journal-title":"Joint Bone Spine."},{"key":"B87","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1136\/annrheumdis-2020-217595","article-title":"DAPSA, carotid plaque and cardiovascular events in psoriatic arthritis: a longitudinal study","volume":"79","author":"Lam","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B88","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/acr.23789","article-title":"Special article: 2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis","volume":"71","author":"Singh","year":"2019","journal-title":"Arthritis Care Res."},{"key":"B89","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13075-019-1810-5","article-title":"Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study","volume":"21","author":"Klingberg","year":"2019","journal-title":"Arthritis Res Ther."},{"key":"B90","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1136\/annrheumdis-2012-202812","article-title":"Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor alpha blockers","volume":"73","author":"Di Minno","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"B91","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1002\/art.40695","article-title":"Effect of achieving minimal disease activity on the progression of subclinical atherosclerosis and arterial stiffness: a prospective cohort study in psoriatic arthritis","volume":"71","author":"Cheng","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"B92","doi-asserted-by":"publisher","first-page":"2881","DOI":"10.1093\/rheumatology\/keaa025","article-title":"Treat to target and prevention of subclinical atherosclerosis in psoriatic arthritis-which target should we choose?","volume":"59","author":"Cheng","year":"2020","journal-title":"Rheumatology."},{"key":"B93","doi-asserted-by":"publisher","first-page":"4379","DOI":"10.1007\/s10067-021-05739-y","article-title":"Psoriatic arthritis and physical activity: a systematic review","volume":"40","author":"Kessler","year":"2021","journal-title":"Clin Rheumatol."},{"key":"B94","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/1744666X.2019.1699058","article-title":"Unmet needs in the management of cardiovascular risk in inflammatory joint diseases","volume":"16","author":"Castaneda","year":"2020","journal-title":"Expert Rev Clin Immunol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1093\/rheumatology\/keaa448","article-title":"Epidemiologic study of patients with psoriatic arthritis in a real-world analysis: a cohort study of the French health insurance database","volume":"60","author":"Pina Vegas","year":"2021","journal-title":"Rheumatology."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.835439\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T19:34:46Z","timestamp":1675193686000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.835439\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,6]]},"references-count":95,"alternative-id":["10.3389\/fcvm.2022.835439"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.835439","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,6]]},"article-number":"835439"}}